On October 9, 2026, HCW Biologics said it remains on track to file an Investigational New Drug (IND) application in the first half of 2027 for HCW11-018b, its lead T-cell engager candidate for solid tumors.
The company said a recent FDA Type B meeting provided guidance on preparing the application for a planned first-in-human cancer study.
Manufacturing of current Good Manufacturing Practice (cGMP) material for clinical trials is underway.
HCW11-018b is part of HCW Biologics’ second-generation, non-Fc-based T-cell engager program and uses its proprietary TRBC platform. The announcement reports development progress—not human trial results.
Sources:
Release Details - HCW Biologics, Inc.
HCW Biologics, Inc.: Investor Relations
HCW Biologics on track for 1H 2027 cancer IND filing
HCW Biologics (HCWB) Stock News & Updates
HCW Biologics receives FDA guidance for cancer drug trial
HCWB Stock Price, News & Analysis
Release Details - HCW Biologics, Inc.
HCW Biologics Maintains Momentum Toward Compl
HCWB Press Releases HCW Biologics
HCW Biologics (HCWB) FDA Approvals
HCW Biologics (Nasdaq:HCWB) - Stock Analysis - Simply Wall St
HCW Biologics Reports FDA Type B Meeting Guidance for ...
HCW Biologics receives FDA guidance for cancer drug trial By Investing.com
HCW Biologics Inc. Stock Price: Quote, Forecast, Splits & ...